Drug details

Enstilar (calcipotriene and betamethasone dipropionate foam, 0.005%/0.064%)

type of Antipsoriatics, Topical

Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, is a combination a vitamin D analog and a corticosteroid, indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• weight loss,
• headache,
• mood changes,
• severe dizziness
• unusual or extreme tiredness,
• vision problems, and
• skin thinning,
• skin discoloration,
• stretch marks,
• swelling or inflammation of the hair pores,
• worsening of psoriasis,
• unexplained constipation,
• swelling of the ankles or feet,
• increased thirst and urination,

The following drugs are related to Enstilar, either as a replacement or used together:

• Soriatane (acitretin)
• Humira (adalimumab injection solution for subcutaneous administration)
• Imraldi (adalimumab-xxxx injection, for subcutaneous use)
• Amevive (alefacept)
• Luxiq (betamethasone valerate foam)
• Wynzora (calcipotriene and betamethasone dipropionate cream)
• Olux (clobetasol propionate)
• Olux-E (clobetasol propionate foam)
• Sandimmune (cyclosporine)
• Raptiva (efalizumab)
• Emerphed (ephedrine sulfate injection)
• Enbrel (etanercept)
• Taltz (ixekizumab injection, for subcutaneous use)
• Stelara Injection (ustekinumab)